51
|
Hypofractionated radiotherapy with Tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions. Clin Exp Metastasis 2013; 30:643-50. [DOI: 10.1007/s10585-013-9568-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2012] [Accepted: 01/18/2013] [Indexed: 12/25/2022]
|
52
|
Al-Jahdali H, Khan AN, Loutfi S, Al-Harbi AS. Guidelines for the role of FDG-PET/CT in lung cancer management. J Infect Public Health 2012; 5 Suppl 1:S35-40. [PMID: 23244185 DOI: 10.1016/j.jiph.2012.09.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET) and PET/computed tomography (FDG-PET/CT) is regarded as a standard of care in the management of non-small-cell lung carcinoma (NSCLC) and is a useful adjunct in the characterization of indeterminate solitary lung nodules (SLN), and pre-treatment staging of NSCLC, notably mediastinal nodal staging and detection of remote metastases. FDG-PET/CT has the ability to assess locoregional lymph node spread more precisely than CT, to detect metastatic lesions that would have been missed on conventional imaging or are located in difficult areas, and to help in the differentiation of lesions that are equivocal after conventional imaging. Increasingly FDG-PET/CT is employed in radiotherapy planning, prediction of prognosis in terms of tumor response to neo-adjuvant, radiation and chemotherapy treatment. Evidence is accumulating of usefulness of PET/CT in small cell lung cancer.
Collapse
Affiliation(s)
- Hamdan Al-Jahdali
- Pulmonary Division, Department of Medicine, King Saud University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia
| | | | | | | |
Collapse
|
53
|
Broderick SR, Crabtree TD. Restaging after induction therapy for non-small-cell lung cancer. Lung Cancer Manag 2012. [DOI: 10.2217/lmt.12.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
SUMMARY Select patients with stage IIIa-N2 non-small-cell lung cancer will benefit from treatment with induction chemoradiotherapy followed by surgical resection. The identification of patients with residual N2 disease may allow for selection of those patients most likely to benefit from resection. The optimal strategy for restaging of mediastinal lymph nodes following induction therapy is controversial. Noninvasive, imaging-based strategies are largely ineffective. Minimally invasive approaches such as endobronchial ultrasound-transbronchial needle aspiration and endoscopic ultrasound-guided fine needle aspiration may identify residual nodal disease, but require surgical confirmation of negative results. Repeat mediastinoscopy may be effective at centers that specialize in this technique, but in the authors opinion its use cannot be broadly recommended. A thoughtful and minimally invasive approach to initial staging of N2 nodes is recommended, reserving mediastinoscopy for restaging whenever possible.
Collapse
Affiliation(s)
- Stephen R Broderick
- Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA
| | - Traves D Crabtree
- Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA
| |
Collapse
|
54
|
Abstract
Selected patients with non small-cell lung cancer (NSCLC) with mediastinal lymph node involvement may have a survival benefit from surgical resection, particularly if mediastinal nodal down-staging occurs after induction therapy and complete resection is achieved with lobectomy. Accurate re-staging of the mediastinum after induction therapy is therefore crucial in determining prognosis and subsequent treatment. Non-invasive imaging techniques usually require a confirmatory tissue sampling method to improve the accuracy of mediastinal re-staging. As in the initial staging of the mediastinum, minimally invasive endosonography-guided needle sampling techniques such as endobronchial ultrasound-guided fine-needle aspiration (EBUS-TBNA) and endoscopic ultrasound-guided fine-needle aspiration show promise in re-staging the mediastinum, though invasive surgical re-staging remains the gold standard. Despite a lower sensitivity in the mediastinal re-staging of NSCLC, EBUS-TBNA with or without EUS-FNA may still be the preferred initial mediastinal re-staging technique.
Collapse
Affiliation(s)
- Kay-Leong Khoo
- National University Health System, Division of Respiratory & Critical Care Medicine, University Medicine Cluster, Singapore
| |
Collapse
|
55
|
Colavolpe C, Bonardel G, Guedj E, Cammilleri S, Mundler O, Barlesi F. [Role of FDG-PET scanning in stage IIIAN2 non-small cell lung cancer]. Rev Mal Respir 2012; 29:149-60. [PMID: 22405110 DOI: 10.1016/j.rmr.2011.05.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2011] [Accepted: 05/28/2011] [Indexed: 12/01/2022]
Abstract
Patients with clinical stage IIIAN2 non-small cell lung cancer (NSCLC) are a heterogeneous subgroup in term of prognosis and therapeutic management. The optimal management of this patient group is a major focus for thoracic oncology research and the concept of multimodality treatment has recently been introduced. This approach combines induction chemotherapy or radiochemotherapy followed by surgery in the case of mediastinal lymph node down-staging. positron emission tomography computed tomography with [18F]-fluorodesoxyglucose (FDG-PET) is a molecular and metabolic imaging modality which combines the metabolic data of PET with morphological data from CT. FDG-PET has become a standard in lung cancer management since the different indications listed in the standards, options and recommendations (SOR) of the FNCLCC. However, the potential specific importance of FDG-PET in IIIAN2 patients needs to be addressed further. In this setting, the authors' objective is to review the potential role of metabolic imaging in stage IIIAN2 NSCLC, taking into account new multimodality treatments. In stage IIIAN2, FDG-PET has performed better than morphoradiological imaging for baseline and postinduction lymph node staging, the identification of distant metastasis, and determining prognosis, as well as assessing the response to treatment.
Collapse
Affiliation(s)
- C Colavolpe
- Service central de biophysique et de médecine nucléaire, CHU La Timone, 264 rue Saint-Pierre, Marseille cedex 5, France.
| | | | | | | | | | | |
Collapse
|
56
|
Miao J, Li H, You B, Hou S, Hu B. Mediastinal Small-Cell Lung Carcinoma after Right Lung Transplant for Pulmonary Interstitial Fibrosis. TUMORI JOURNAL 2012; 98:e39-e42. [DOI: 10.1177/030089161209800220] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Pulmonary carcinoma is uncommon after lung transplant, but doubtlessly affects recipient survival independently of other complications. Small cell lung cancer is much rarer after transplant than non-small cell lung cancer. We report a case of mediastinal small cell lung carcinoma confirmed by endobronchial ultrasound biopsy that occurred 18 months after a single lung transplant for interstitial pulmonary fibrosis in a 58-year-old male non-smoker. The patient died shortly after of distant metastasis. Our report confirms the usefulness of tumor markers and positron-emission tomography-computed tomography as routine tests for earlier detection of malignant disease after lung transplant.
Collapse
Affiliation(s)
- Jinbai Miao
- Department of Thoracic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Hui Li
- Department of Thoracic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Bin You
- Department of Thoracic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Shengcai Hou
- Department of Thoracic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Bin Hu
- Department of Thoracic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
57
|
|
58
|
Rami-Porta R, Call S. Invasive staging of mediastinal lymph nodes: mediastinoscopy and remediastinoscopy. Thorac Surg Clin 2011; 22:177-89. [PMID: 22520285 DOI: 10.1016/j.thorsurg.2011.12.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Nodal status in lung cancer is essential for planning therapy and assessing prognosis. The involvement of ipsilateral and contralateral mediastinal lymph nodes is associated with poor prognosis and usually excludes patients from upfront surgical treatment. Mediastinoscopy is a time-honored procedure that allows the surgeon to access the upper mediastinal lymph nodes for either biopsy or removal. Remediastinoscopy is mainly indicated to assess objective tumor response in mediastinal lymph nodes after induction therapy for locally advanced lung cancer and to indicate further therapy.
Collapse
Affiliation(s)
- Ramón Rami-Porta
- Thoracic Surgery Service, Hospital Universitari Mutua Terrassa, University of Barcelona, Plaza Drive Robert 5, 08221 Terrassa, Barcelona, Spain.
| | | |
Collapse
|
59
|
Marra A, Richardsen G, Wagner W, Müller-Tidow C, Koch OM, Hillejan L. Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment. THORACIC SURGICAL SCIENCE 2011; 8:Doc01. [PMID: 22205919 PMCID: PMC3246278 DOI: 10.3205/tss000021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Objective: To investigate the prognostic significance of location and extent of lymph node metastasis in resected non-small cell lung cancer (NSCLC), and to weigh up the influence of treatment modalities on survival. Patients and method: On exploratory analysis, patients were grouped according to location and time of diagnosis of nodal metastasis: group I, pN2-disease in the aortopulmonary region (N=14); group II, pN2-disease at other level (N=30); group III, cN2-disease with response to induction treatment (ypN0; N=21); group IV, cN2-disease without response to induction treatment (ypN1-2; N=27); group V, pN1-disease (N=66). Results: From 1999 to 2005, 158 patients (median age: 64 years) with node-positive NSCLC were treated at our institution either by neoadjuvant chemo-radiotherapy plus surgery or by surgery plus adjuvant therapy (chemotherapy, radiotherapy, or both). Operative mortality and major morbidity rates were 2% and 15%. Five-year survival rates were 19% for group I, 12% for group II, 66% for group III, 15% for group IV, and 29% for group V (P<.05). On multivariate analysis, time of N+-diagnosis, extent of nodal involvement and therapy approach were significantly linked to prognosis. Conclusion: The survival of patients with node-positive NSCLC does not depend on anatomical location of nodal disease, but strongly correlates to extent of nodal metastases and treatment modality. Combined therapy approaches including chemotherapy and surgery may improve long-term survival.
Collapse
Affiliation(s)
- Alessandro Marra
- Dept. of Thoracic Surgery, Niels-Stensen-Kliniken, Ostercappeln, Germany
| | | | | | | | | | | |
Collapse
|
60
|
Transesophageal ultrasound-guided fine-needle aspiration for the mediastinal restaging of non-small cell lung cancer. J Thorac Oncol 2011; 6:1510-5. [PMID: 21642873 DOI: 10.1097/jto.0b013e31821e1a64] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
INTRODUCTION Selected patients with stage III (N2/N3) non-small cell lung cancer (NSCLC) who are downstaged to N0 by chemoradiation therapy might benefit from subsequent surgical resection of the tumor. How mediastinal lymph nodes can be best reevaluated is subject of debate. Transesophageal ultrasound-guided fine-needle aspiration (EUS-FNA) is a minimally invasive technique to sample mediastinal nodes. We assessed sensitivity and false-negative rate of EUS-FNA for the mediastinal restaging of patients with stage III NSCLC. METHODS Fifty-eight consecutive patients with stage III NSCLC and tissue-proven lymph node metastases N2/N3) who underwent EUS-FNA for restaging purposes after chemoradiation therapy were retrospectively analyzed. Surgical-pathological staging was used as the reference standard for nodal metastases. RESULTS EUS-FNA found persistent nodal metastases (N2/N3) in 15 patients (26%). Of the 43 patients without persistent mediastinal metastases at EUS, 33 patients subsequently underwent surgical verification of the mediastinal nodes in whom persistent metastases (yN2/N3) were found in 19 patients (58%), and loco-regional downstaging (yN0) was achieved in the other 14 (42%). The prevalence of persistent nodal metastases in the 48 patients who could be analyzed was 71%. Sensitivity and the false-negative rate of EUS-FNA for mediastinal restaging were 44 and 58%, respectively. DISCUSSION For mediastinal restaging of stage III NSCLC, EUS-FNA is a minimally invasive and safe method to confirm persistent nodal metastases, but this technique has a low negative predictive value and is therefore not useful for the exclusion of mediastinal metastases. Surgical restaging is indicated in the absence of mediastinal metastases at EUS-FNA.
Collapse
|
61
|
Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol 2011; 6:1350-8. [PMID: 21642874 DOI: 10.1097/jto.0b013e31821d4384] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Accurate clinical staging of mediastinal lymph nodes (MLNs) of patients with non-small cell lung cancer (NSCLC) is important in determining therapeutic options and prognoses. Integrated positron emission tomography and computed tomography (PET/CT) scanning is becoming widely used for MLN staging in patients with NSCLC. We performed a bivariate meta-analysis to determine the pooled sensitivity (SEN) and specificity (SPE) of this imaging modality. METHODS The PubMed/MEDLINE, Embase, and SpringerLink databases were searched for articles related to PET/CT for MLN staging in patients with NSCLC. SEN and SPE were calculated for every study. Hierarchical summary receiver operating characteristic curves were used to summarize overall test performance and assess study quality. Potential between-study heterogeneity was explored by subgroup analyses. RESULTS Fourteen of 330 initially identified reports were included in the meta-analysis. When we did not consider the unit of analysis, the pooled weighted SEN and SPE were 0.73 (95% confidence interval [CI]: 0.65-0.79) and 0.92 (95% CI: 0.88-0.94), respectively. In the patient-based data analysis, the pooled weighted SEN was 0.76 (95% CI: 0.65-0.84) and the pooled weighted SPE was 0.88 (95% CI: 0.82-0.92). In the MLN-based data analysis, the pooled SEN was 0.68 (95% CI: 0.56-0.78) and the pooled SPE was 0.95 (95% CI: 0.91-0.97). CONCLUSIONS Integrated PET/CT is a relatively accurate noninvasive imaging technique, with excellent specificity for MLN staging in patients with NSCLC. Nevertheless, current evidence suggests that we should not depend on the results of PET/CT completely for MLN staging in patients with NSCLC.
Collapse
|
62
|
Collaud S, Lardinois D, Tischler V, Steinert HC, Stahel R, Weder W. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer. Eur J Cardiothorac Surg 2011; 41:612-6. [PMID: 22219415 DOI: 10.1093/ejcts/ezr109] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES Restaging of patients with locally advanced non-small-cell lung cancer (NSCLC) is of paramount importance, since only patients with down-staging after induction therapy will benefit from surgery. In this study, we assessed the aetiology of new (18)fluoro-2-deoxy-d-glucose (FDG)-positive focal abnormalities on restaging positron emission tomography/computed tomography (PET/CT) in patients with a good response after induction chemotherapy in the primary tumour and lymph nodes. METHODS Between 2004 and 2008, 31 patients with histological proven stage III NSCLC had a PET/CT prior and after induction chemotherapy. Their medical charts were retrospectively reviewed. RESULTS Restaging PET/CT revealed a new FDG-positive lesion in 6 of 31 (20%) patients. The initial clinical stage of the disease was IIIA N2 in four and IIIB T4 in two patients. The maximal standard uptake value in the primary tumour (P = 0.043) and in the initially involved mediastinal nodes (P = 0.068) decreased after induction treatment in all patients. The new PET/CT findings were located in an ipsilateral cervical lymph node in two patients, a contralateral mediastinal in one patient and an ipsilateral mammary internal lymph node in one patient. Two other patients had a lesion on the contralateral lung. Malignant lymph node infiltrations were excluded following fine-needle puncture, intraoperative biopsy or follow-up PET/CT. Contralateral pulmonary lesions were diagnosed as benign following mini thoracotomy and pulmonary wedge resection. CONCLUSIONS New solitary FDG-positive lesions on restaging PET/CT after induction chemotherapy for NSCLC are not rare in good responders to chemotherapy. In our experience, all these lesions were not associated with malignancy.
Collapse
Affiliation(s)
- Stéphane Collaud
- Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
| | | | | | | | | | | |
Collapse
|
63
|
Yanagawa J, Rusch VW. Current Surgical Therapy for Stage IIIA (N2) Non-Small Cell Lung Cancer. Semin Thorac Cardiovasc Surg 2011; 23:291-6. [DOI: 10.1053/j.semtcvs.2011.12.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/18/2011] [Indexed: 11/11/2022]
|
64
|
[Indications for surgery in non-small cell lung cancer with lymph node invasion]. Rev Mal Respir 2011; 28:960-6. [PMID: 22099401 DOI: 10.1016/j.rmr.2011.01.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2010] [Accepted: 01/26/2011] [Indexed: 12/25/2022]
Abstract
Surgery is indicated for N1 non-small cell lung cancer and performed, with good results in some patients, when N2 disease is not diagnosed preoperatively "minimal N2". Following the publication of the "EORTC 08941" and "Intergroup 0139" trials, it remains debatable for patients with proven N2 disease. Good prognostic factors before treatment or post-induction favour surgery, which seems superior to radiochemotherapy if the operative risk is low (lobectomies, and some pneumonectomies). N3 status is a contraindication to surgery, except in some rare cases with a strong response to induction treatment.
Collapse
|
65
|
Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria. Eur Radiol 2011; 22:588-606. [DOI: 10.1007/s00330-011-2299-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2011] [Revised: 09/06/2011] [Accepted: 09/12/2011] [Indexed: 12/18/2022]
|
66
|
Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy. Ann Thorac Surg 2011; 92:e11-2. [PMID: 21718818 DOI: 10.1016/j.athoracsur.2011.02.021] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2010] [Revised: 01/15/2011] [Accepted: 02/07/2011] [Indexed: 11/20/2022]
Abstract
First-line therapy with gefitinib prolongs progression-free survival and improves quality of life among selected patients with non-small cell lung cancer. Selected locally advanced patients may derive benefit from surgical resection after gefitinib therapy. Further clinical trials are needed to evaluate the role of gefitinib therapy followed by surgical resection.
Collapse
|
67
|
|
68
|
Sánchez de Cos J, Hernández JH, López MFJ, Sánchez SP, Gratacós AR, Porta RR. SEPAR guidelines for lung cancer staging. Arch Bronconeumol 2011; 47:454-65. [PMID: 21824707 DOI: 10.1016/j.arbres.2011.06.013] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2011] [Accepted: 06/27/2011] [Indexed: 11/28/2022]
Abstract
The latest tumour, lymph node and metastasis (TNM) classification by the International Association for the Study of Lung Cancer (IASLC), based on the analysis of patients from all over the world, has incorporated changes in the descriptors, especially those regarding tumor size, while proposing new group staging. A new lymph node map has also been developed with the intention of facilitating the classification of the "N" component. SEPAR recommends using this new classification. As for the procedures recommended for staging, in addition to the generalized use of computed tomography (CT), it points to the role of positron emission tomography (PET) or image fusion methods (PET/CT), which provide a better evaluation of the mediastinum and extrathoracic metastases. Endobronchial ultrasound (EBUS) and esophageal ultrasound (EUS) for obtaining cytohistological samples have been incorporated in the staging algorithm, and it emphasizes the importance of precise re-staging after induction treatment in order to make new therapeutic decisions. Comment is made on the foreseeable incorporation in the near future of molecular staging, and systematic lymph node dissection is recommended with the intention of making a more exact surgical-pathological classification.
Collapse
|
69
|
Delappe E, Dunphy M. 18F-2-Deoxy-d-Glucose positron emission tomography-computed tomography in lung cancer. Semin Roentgenol 2011; 46:208-23. [PMID: 21726705 DOI: 10.1053/j.ro.2011.02.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Eithne Delappe
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
| | | |
Collapse
|
70
|
Louie BE, Kapur S, Farivar AS, Youssef SJ, Gorden J, Aye RW, Vallières E. Safety and Utility of Mediastinoscopy in Non-Small Cell Lung Cancer in a Complex Mediastinum. Ann Thorac Surg 2011; 92:278-82; discussion 282-3. [DOI: 10.1016/j.athoracsur.2011.02.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2010] [Revised: 01/29/2011] [Accepted: 02/04/2011] [Indexed: 10/18/2022]
|
71
|
Anraku M, Pierre AF, Nakajima T, de Perrot M, Darling GE, Waddell TK, Keshavjee S, Yasufuku K. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Management of Previously Treated Lung Cancer. Ann Thorac Surg 2011; 92:251-5; discussion 255. [DOI: 10.1016/j.athoracsur.2011.03.007] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2010] [Revised: 02/25/2011] [Accepted: 03/07/2011] [Indexed: 11/27/2022]
|
72
|
Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures. Eur J Cardiothorac Surg 2011; 39:1022-7. [DOI: 10.1016/j.ejcts.2010.10.019] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2010] [Revised: 10/05/2010] [Accepted: 10/11/2010] [Indexed: 11/24/2022] Open
|
73
|
Schuhmann M, Eberhardt R, Herth FJF. Direct nodal sampling by echoendoscopy in lung cancer: the clinician's expectations: Direct nodal sampling by echoendoscopy in lung cancer. Insights Imaging 2011; 2:133-140. [PMID: 22347942 PMCID: PMC3259317 DOI: 10.1007/s13244-010-0058-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2010] [Revised: 11/01/2010] [Accepted: 12/09/2010] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND: Mediastinal lymph node staging for lung cancer remains one of the most important factors to determine patient outcome. METHODS: Noninvasive imaging techniques such as CT, MRI, PET and PET-CT provide some answers but no tissue diagnosis. RESULTS: The development of endo-oesophageal (EUS) and endobronchial ultrasound (EBUS) with fine-needle aspiration has provided the clinician with a tool to investigate the mediastinum and the adrenal gland with a safe, minimally invasive procedure that can be performed on an outpatient basis. CONCLUSION: The aim of this article was to give radiologists an overview of the techniques of EUS and EBUS and their role in the staging of lung cancer patients.
Collapse
Affiliation(s)
- Maren Schuhmann
- Department of Pneumonology and Critical Care Medicine, Thoraxklinik at University Hospital Heidelberg, Amalienstr. 5, 69126 Heidelberg, Germany
- Southampton University Hospital Trust, Southampton, UK
| | - Ralf Eberhardt
- Department of Pneumonology and Critical Care Medicine, Thoraxklinik at University Hospital Heidelberg, Amalienstr. 5, 69126 Heidelberg, Germany
| | - Felix J. F. Herth
- Department of Pneumonology and Critical Care Medicine, Thoraxklinik at University Hospital Heidelberg, Amalienstr. 5, 69126 Heidelberg, Germany
| |
Collapse
|
74
|
Vaylet F, Margery J, Bonardel G, Le Floch H, Rivière F, Gontier E, Ngampolo I, Mairovitz A, Marotel C, Foehrenbach H. [What is the role of FDG-PET in thoracic oncology in 2010?]. REVUE DE PNEUMOLOGIE CLINIQUE 2010; 66:221-238. [PMID: 20933164 DOI: 10.1016/j.pneumo.2010.07.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2010] [Accepted: 06/28/2010] [Indexed: 05/30/2023]
Abstract
18F-Fluorodeoxyglucose-Positron Emission Tomography (FGD-PET) has been considered to have a major impact on the management of lung malignancies since the beginning of this century. Its value has been demonstrated by many publications, meta-analysis and European/American/Japanese recommendations. PET combined with computed tomography has provided useful information regarding the diagnosis and staging of lung cancer and allows for the delivery of adaptive radiotherapy. In its more common uses, PET has been shown to be cost-effective. With the widespread use of new radiotracers, PET will play an increasing role in the evaluation of response to treatment.
Collapse
Affiliation(s)
- F Vaylet
- Service des maladies respiratoires, hôpital d'instruction des armées Percy, 92140 Clamart, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
75
|
Groth SS, Andrade RS. Endobronchial and endoscopic ultrasound-guided fine-needle aspiration: a must for thoracic surgeons. Ann Thorac Surg 2010; 89:S2079-83. [PMID: 20493985 DOI: 10.1016/j.athoracsur.2010.03.018] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2009] [Revised: 03/01/2010] [Accepted: 03/04/2010] [Indexed: 12/12/2022]
Abstract
A thoracic surgeon facile in endobronchial ultrasound-guided fine-needle aspiration (EBUS-FNA) and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) can accurately sample mediastinal lymph nodes (MLNs) for histologic assessment of mediastinal adenopathy and for thoracic malignancy staging. Although mediastinoscopy is the gold standard for histologic MLN assessment, EBUS-FNA and EUS-FNA have emerged as useful, less-invasive sampling techniques that offer access to a wider range of MLN stations than mediastinoscopy and can be used to biopsy suspicious lesions within (ie, peribronchial masses) and outside the mediastinum (ie, left adrenal gland masses, liver lesions, and enlarged celiac lymph nodes). The negative predictive value of EBUS-TBNA and EUS-FNA in patients with malignancy is somewhat lower than the negative predictive value of mediastinoscopy. Therefore, we recommend that nonmalignant EBUS or EUS cytologic findings should be confirmed with a surgical MLN biopsy (ie, mediastinoscopy or thoracoscopy) if the pretest probability of malignancy is high.
Collapse
Affiliation(s)
- Shawn S Groth
- Division of General Thoracic and Foregut Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | | |
Collapse
|
76
|
Coche E, Lonneux M, Geets X. Lung cancer: Morphological and functional approach to screening, staging and treatment planning. Future Oncol 2010; 6:367-80. [PMID: 20222794 DOI: 10.2217/fon.10.7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Lung cancer is a major problem in public health and constitutes the leading cause of cancer-related mortality in the world. Lung cancer screening with low-dose computed tomography is promising but needs to overcome many difficulties, such as the large number of incidentally discovered nodules, the radiation dose delivered to the patient during a whole screening program and its cost. The ultimate target point represented by the reduction of lung cancer-related mortality needs to be proved in large, well-designed, randomized, multicenter, prospective trials. Lung cancer staging by morphological tools seems to be limited owing to the presence of metastases in normal-sized lymph nodes. In this context, multidetector computed tomography cannot be used alone but is useful in conjunction with molecular imaging and MRI. Today, flurodeoxglucose PET-CT appears to be the most accurate method for lung cancer staging and may prevent unnecessary thoracotomies. For treatment planning, flurodeoxglucose PET-CT is playing an increasing role in radiotherapy planning at the target selection and definition steps.
Collapse
Affiliation(s)
- Emmanuel Coche
- Department of Medical Imaging, Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium.
| | | | | |
Collapse
|
77
|
Anraku M, Miyata R, Compeau C, Shargall Y. Video-assisted mediastinoscopy compared with conventional mediastinoscopy: are we doing better? Ann Thorac Surg 2010; 89:1577-81. [PMID: 20417780 DOI: 10.1016/j.athoracsur.2010.02.012] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2009] [Revised: 02/07/2010] [Accepted: 02/09/2010] [Indexed: 11/24/2022]
Abstract
BACKGROUND Conventional mediastinoscopy (CM) is recently being replaced by video-assisted mediastinoscopy (VAM), with potentially better yield and better safety profile for VAM. METHODS All 645 mediastinoscopies (505 CM, 140 VAM) performed between May 2004 and May 2008 were reviewed. Numbers of stations biopsied, total number of lymph nodes dissected, pathology results, and complications were recorded. Patients were divided into two groups: staging for lung cancer group (n = 500) and diagnostic group (n = 145). The staging group was further analyzed, using 304 patients who eventually underwent thoracotomy to evaluate accuracy and negative predictive value of mediastinoscopy, comparing between the two methods (233 CM, 71 VAM). RESULTS Average age was 65 years (range, 26 to 91), and 382 were male. There was no mortality. Eight complications (1.2%) occurred, more in the VAM group (3.8%) than in the CM group (0.8%; p = 0.04). The total number of dissected nodes was higher in the VAM group than in the CM group (7.0 +/- 3.2 versus 5.0 +/- 2.8, p < 0.001), and so was the number of stations sampled (3.6 versus 2.6, p < 0.01). Sensitivity was higher for VAM (95% versus 92.2%, p = not significant), and so was the negative predictive value (98.6% versus 95.7%, p = not significant). Most false negative biopsies (8 of 11, 73 %) occurred in station 7. CONCLUSIONS Both methods are safe. More lymph nodes and stations were evaluated by VAM, with trend toward higher negative predictive value. The higher rate of minor complications seen with VAM might be related to a more aggressive and thorough dissection.
Collapse
Affiliation(s)
- Masaki Anraku
- Division of Thoracic Surgery, St Joseph's Health Centre, University of Toronto, Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
78
|
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Evaluation of Suspected Lymphoma. J Thorac Oncol 2010; 5:804-9. [DOI: 10.1097/jto.0b013e3181d873be] [Citation(s) in RCA: 119] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
79
|
Vansteenkiste J, Van Damme V, Dooms C. Generalized or personalized treatment for stage IIIA-N2 non-small-cell lung cancer? Expert Opin Pharmacother 2010; 11:1605-9. [DOI: 10.1517/14656566.2010.481285] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
80
|
Houtte PV. Lung cancer: from staging to treatment - a summary of an international meeting. Expert Rev Respir Med 2010; 3:221-5. [PMID: 20477316 DOI: 10.1586/ers.09.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The 10th European Congress: Perspectives in Lung Cancer meeting was held in early March 2009 in Brussels. This was an extensive overview of the management of lung cancer and mesothelioma, from diagnosis to treatment, including surgery, chemotherapy and targeted therapies, and also supportive treatments.
Collapse
Affiliation(s)
- Paul Van Houtte
- Department of Radiation Oncology, Institut Jules Bordet, Université Libre de Bruxelles, 121 boulevard de Waterloo, 1000 Brussels, Belgium.
| |
Collapse
|
81
|
Lerut T, De Leyn P, Coosemans W, Decaluwé H, Decker G, Nafteux P, Van Raemdonck D. Cervical Videomediastinoscopy. Thorac Surg Clin 2010; 20:195-206. [DOI: 10.1016/j.thorsurg.2010.01.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
82
|
Rebollo-Aguirre AC, Ramos-Font C, Villegas Portero R, Cook GJR, Llamas Elvira JM, Romero Tabares A. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. J Surg Oncol 2010; 101:486-94. [PMID: 20213693 DOI: 10.1002/jso.21525] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Neoadjuvant therapy response assessment is crucial in patients with non-small cell lung cancer (NSCLC). FDG-PET has emerged as a valuable tool for defining therapy response assessment in other tumours. AIM To systematically review publications appearing in the literature describing induction therapy response assessment with FDG-PET in NSCLC. METHODS We performed a bibliographic search and selected only prospective studies in order to include the highest levels of evidence. RESULTS Nine of 497 potentially relevant publications were selected. The ranges of sensitivity, specificity, positive predictive value and negative predictive value for primary tumour response assessment were 80-100%, 0-100%, 42.9-100%, and 66.7-100%, respectively. Pooling data for N2 restaging after neoadjuvant response the overall sensitivity was 63.8% (95% CI, 53.3-73.7%) and overall specificity was 85.3% (95% CI, 80.4-89.4%). CONCLUSION The results of the analysis do not support the use of FDG-PET as the only re-assessment tool for mediastinal lymph node evaluation for routine clinical use. FDG-PET seems to predict primary tumour response to induction therapy but it could not be shown by pooling analysis.
Collapse
|
83
|
A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage. J Thorac Oncol 2010; 5:389-98. [PMID: 20186025 DOI: 10.1097/jto.0b013e3181ce3e5e] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
84
|
Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer. Curr Opin Oncol 2010; 22:102-11. [DOI: 10.1097/cco.0b013e328335c076] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
85
|
Rodríguez N, Sanz X, Trampal C, Foro P, Reig A, Lacruz M, Membrive I, Lozano J, Quera J, Algara M. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation? Int J Radiat Oncol Biol Phys 2010; 78:659-66. [PMID: 20133071 DOI: 10.1016/j.ijrobp.2009.08.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2009] [Revised: 08/09/2009] [Accepted: 08/13/2009] [Indexed: 11/17/2022]
Abstract
PURPOSE Positron emission tomography (PET) with the glucose analogue [18F] fluoro-2-deoxy-D-glucose ((18)F-FDG-PET) has been used in radiation treatment planning for non-small-cell carcinoma. To date, lymph nodes have been contoured according to the uptake of the tumor. This prospective study was performed to evaluate if nodal volume delineates according to FDG uptake within the primary tumor (PET-GTVnt) is suitable for nodal target volume delineation or if individualized nodal FDG uptake measure (PET-GTVnn) is necessary to better nodal target definition. METHODS AND MATERIALS Forty cases, who underwent a diagnostic (18)F-FDG PET/computed tomography (CT) scan, were included. Two PET-based GTVs for each lymph node were contoured and compared. First, we used an isocontour of 40% of the maximum tumor uptake (PET-GTVnt). Second, an isocontour of 40% of the maximum uptake of each node (PET-GTVnn) was employed. To avoid interobserver variability, this was carried out by the same radiation oncologist. Afterwards, the difference between both lymph node volumes was plotted against the ratio of the maximum uptakes (I(n)/I(t)) in a linear regression analysis. RESULTS Compared with CT-based lymph node volume (CT-GTVn), the intraclass correlation coefficient of PET-GTVnn was higher than the coefficient of PET-GTVnt (p < 0.001). All cases could be divided into four groups: undetected (17.5%), detected but overestimated (10%), detected but underestimated (35%), and correctly detected (37.5%). CONCLUSIONS If a method of automatic delineation shall be applied, this method must be applied to every lesion separately. However, to facilitate the delineation in daily practice, when I(n)/I(t) is ≤25%, lymph nodes could be delineated in accordance with tumor uptake, keeping an absolute difference in radii <5 mm.
Collapse
Affiliation(s)
- Núria Rodríguez
- Department of Radiation Oncology, Hospitales de la Esperanza y del Mar, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
86
|
Czernin J, Benz MR, Allen-Auerbach MS. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol 2010; 73:470-80. [PMID: 20097498 DOI: 10.1016/j.ejrad.2009.12.023] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2009] [Accepted: 12/15/2009] [Indexed: 01/12/2023]
Abstract
PET/CT with the glucose analogue FDG is emerging as the most important diagnostic imaging tool in oncology. More than 2000 PET/CT scanners are operational worldwide and its unique role for diagnosing, staging, restaging and therapeutic monitoring in cancer is undisputed. Studies conducted in thousands of cancer patients have clearly indicated that the combination of molecular PET with anatomical CT imaging provides incremental diagnostic value over PET or CT alone. State of the art imaging protocols combine fully diagnostic CT scans with quality whole body PET surveys. The current review briefly describes the biological alterations of cancer cells that result in their switch to a strongly glycolytic phenotype. Different whole body imaging protocols are discussed. We summarize the evidence for the incremental value of PET/CT over CT and PET alone using imaging of sarcoma as an example. Following this section we discuss the performance of FDG-PET/CT imaging for staging, restaging and monitoring of head and neck cancer, solitary lung nodules and lung cancer, breast cancer, colorectal cancer, lymphoma and unknown primary tumors. Finally, the recently emerging evidence of a substantial impact of PET/CT imaging on patient management is presented.
Collapse
Affiliation(s)
- Johannes Czernin
- Department of Molecular and Medical Pharmacology, Ahmanson Biological, Imaging Center/Nuclear Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-6948, USA.
| | | | | |
Collapse
|
87
|
Stigt JA, Oostdijk AH, Timmer PR, Shahin GM, Boers JE, Groen HJ. Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restaging after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2009; 66:198-204. [PMID: 19231024 DOI: 10.1016/j.lungcan.2009.01.013] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2008] [Revised: 01/13/2009] [Accepted: 01/19/2009] [Indexed: 12/25/2022]
|
88
|
Abstract
PURPOSE OF REVIEW To describe the state-of-the-art of the surgical management of stage IIIA-N2 nonsmall cell lung cancer. RECENT FINDINGS When completely resected, occult N2 found at thoracotomy, skip metastases, and single-level N2 in selected locations are reported to portend acceptable survival rates. Conversely, preoperatively proven ipsilateral mediastinal nodal involvement requires a multidisciplinary approach on the basis of neoadjuvant chemotherapy or chemoradiation. In these patients, complete resection of the primary tumor remains among the strongest prognosticators of survival. When technically feasible, radical mediastinal lymphadenectomy could be of added value. Given the demonstrated increase in postoperative morbidity and mortality, pneumonectomy should be avoided when possible, whereas lobectomy and parenchymal sparing resections should be favored if compatible with the resection of the original extent of the primary on tumor-free margins. SUMMARY Only selected patients with N2 disease may benefit from primary surgery. The impact of postoperative morbidity after induction treatment is still being evaluated. In this setting, differences in treatment sequence and combination (chemotherapy alone or chemoradiation) may influence postsurgical outcome. Patients' selection revolves around the modern concepts of oncologic operability and surgical resectability intended as assessment of survival benefit and ability to completely resect all residual tumor after neoadjuvant therapy.
Collapse
|
89
|
van Meerbeeck JP, Surmont VF. Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developments. Lung Cancer 2009; 65:257-67. [DOI: 10.1016/j.lungcan.2009.02.007] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2008] [Revised: 01/10/2009] [Accepted: 02/07/2009] [Indexed: 11/29/2022]
|
90
|
|
91
|
Browner I, Purtell M. Chemotherapy in the Older Patient with Operable Non–Small Cell Lung Cancer: Neoadjuvant and Adjuvant Regimens. Thorac Surg Clin 2009; 19:377-89. [DOI: 10.1016/j.thorsurg.2009.07.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
92
|
Abstract
Mediastinal staging of non-small-cell lung cancer (NSCLC) is of paramount importance. It distinguishes operable from inoperable disease, guides prognosis and allows accurate comparison of outcomes in clinical trials. Noninvasive imaging modalities for mediastinal staging include CT, PET and integrated PET-CT. Mediastinoscopy is considered the current gold standard; however, each of these techniques has limitations in sensitivity or specificity. These inadequacies mean that 10% of operations performed with curative intent in patients with NSCLC are futile, owing to inaccurate locoregional lymph-node staging. Endoscopic and endobronchial ultrasound-guided mediastinal lymph-node aspiration are important and promising innovative techniques with reported sensitivities and specificities higher than standard investigations. The role of these techniques in mediastinal lymph-node staging is evolving rapidly and early data suggest that they may diminish the need for invasive surgical staging of the mediastinum. Furthermore, these are outpatient procedures that do not require general anesthesia and may be combined safely in the same sitting, for optimal accuracy of mediastinal staging. We propose a new algorithm for the diagnosis and staging of NSCLC, based on the current evidence, which incorporates endoscopic and endobronchial ultrasound as a first investigation after CT in patients with intrathoracic disease.
Collapse
|
93
|
Medford ARL, Bennett JA, Free CM, Agrawal S. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med 2009; 15:334-42. [PMID: 19395972 DOI: 10.1097/mcp.0b013e32832b8a45] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE OF REVIEW There is increasing awareness of minimally invasive endoscopic techniques for mediastinal staging in lung cancer. Traditionally, cervical mediastinoscopy has been utilized. Endobronchial ultrasound-guided fine needle aspiration (EBUS) has recently emerged as a potential alternative. RECENT FINDINGS EBUS has sensitivity for lung cancer which is at least equivalent (if not superior) to cervical mediastinoscopy. However, cervical mediastinoscopy remains superior to EBUS and other techniques in its high negative predictive value. More recent data suggest EBUS may have a role in presurgical staging of radiologically normal subcentimetre nodes and its negative predictive value may be equivalent to surgical staging. Ongoing comparative studies between EBUS and cervical mediastinoscopy may well clarify relative performance and cost analyses. SUMMARY Currently, insufficient data are present to recommend replacing cervical mediastinoscopy with EBUS for lung cancer staging; the negative predictive value of EBUS requires validation. However, EBUS can be recommended for initial staging as a minimally invasive option provided negative results are followed by cervical mediastinoscopy. This would also allow cervical mediastinoscopy to be reserved for re-staging. Conventional transbronchial needle aspiration has a limited role only as a first-line staging procedure but may aid diagnosis. In the future, EBUS may have a role in presurgical staging of the radiologically normal mediastinum and re-staging if prior staging is done by cervical mediastinoscopy.
Collapse
Affiliation(s)
- Andrew R L Medford
- Department of Respiratory Medicine, Allergy and Thoracic Surgery, Institute for Lung Health, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester LE3 9QP, Leicestershire, UK.
| | | | | | | |
Collapse
|
94
|
|
95
|
Ratto GB, Costa R, Maineri P, Alloisio A, Bruzzi P, Dozin B. Is there a subset of patients with preoperatively diagnosed N2 non-small cell lung cancer who might benefit from surgical resection? J Thorac Cardiovasc Surg 2009; 138:849-58. [PMID: 19660370 DOI: 10.1016/j.jtcvs.2009.03.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2008] [Revised: 02/06/2009] [Accepted: 03/08/2009] [Indexed: 12/15/2022]
Abstract
OBJECTIVE The role of surgery in the treatment of preoperatively diagnosed N2 non-small cell lung cancer remains controversial. This study sought significant prognostic factors to select candidates for surgery and assess prognosis. METHODS The study population included 277 patients who underwent primary resection (192) or induction chemotherapy followed by surgery (85) for preoperatively diagnosed, potentially resectable N2 non-small cell lung cancer. N2 descriptors were prospectively recorded. Kaplan-Meier curves were used to evaluate survival, and statistical significance of differences between curves was assessed by log-rank test. Cox regression was used for multivariate analyses. RESULTS Preoperative significant prognostic factors were number of mediastinal node levels involved (P < .001), symptom severity (P = .013), clinical T (P = .041), and induction chemotherapy (P = .001). Three groups with different prognoses were based on individual prognostic score. The group that did best had a median survival of 29.6 months. Postoperative predictors of survival were pathologic T (P = .003), tumor residue (P = .034), and number of mediastinal nodes involved (P < .001). Of 3 groups with different prognoses, the most favorable had a median survival as long as 42 months. CONCLUSION This study provides a practical tool that uses significant prognostic factors to predict which patients with preoperatively diagnosed N2 non-small cell lung cancer have better prognoses. Because patients with the favorable prognostic factors showed good long-term survival and excellent local disease control, surgery should still play an important role in the multimodality treatment of these patients.
Collapse
Affiliation(s)
- Giovanni B Ratto
- Unit of Thoracic Surgery, Department of Surgical Oncology, National Cancer Research Institute, Genoa, Italy.
| | | | | | | | | | | |
Collapse
|
96
|
Groth SS, Andrade RS. Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal lymph node staging in non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2009; 20:274-8. [PMID: 19251164 DOI: 10.1053/j.semtcvs.2008.11.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/04/2008] [Indexed: 12/25/2022]
Abstract
Mediastinoscopy is the gold standard for mediastinal lymph node (MLN) staging for non-small cell lung cancer patients; however, mediastinoscopy is invasive and allows access to a limited number of American Thoracic Society MLN stations (1, 2, 3, 4, and 7). Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is emerging as a useful, less invasive staging technique that offers access to a wider range of MLN stations (2, 3, 4, 7, 10, and 11). Although EBUS-TBNA has excellent sensitivity and diagnostic accuracy, an alternative MLN biopsy technique (i.e., mediastinoscopy or thoracoscopy) is required to confirm negative cytology findings, especially after induction therapy. Additionally, an experienced cytopathologist is critical to establishing an effective EBUS-TBNA program.
Collapse
Affiliation(s)
- Shawn S Groth
- Division of Thoracic and Foregut Surgery, Department of Surgery, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
| | | |
Collapse
|
97
|
Pinilla I, Gómez León N. [The usefulness of PET/CT in lung cancer]. RADIOLOGIA 2009; 51:248-60. [PMID: 19406442 DOI: 10.1016/j.rx.2009.01.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2008] [Accepted: 01/09/2009] [Indexed: 12/20/2022]
Abstract
Lung cancer is the leading cause of cancer-related death. Accurate staging is essential for the optimal management and treatment of these patients. Positron emission tomography (PET) and, more recently, PET/CT have been introduced into the diagnostic algorithms for oncologic patients because they provide valuable functional information. The hybrid PET/CT technique acquires both anatomic (CT) and metabolic (PET) images in a single session, combining the benefits of each modality and minimizing their limitations. This article reviews the role of PET/CT in lung cancer staging, with emphasis on non-small cell carcinoma, evaluating the advantages and limitations of the technique. Other applications of the technique, such as planning radiotherapy, are also discussed.
Collapse
Affiliation(s)
- I Pinilla
- Servicio de Radiodiagnóstico, Hospital Universitario La Paz, Madrid, España.
| | | |
Collapse
|
98
|
Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009; 70:382-92. [PMID: 19406595 DOI: 10.1016/j.ejrad.2009.03.051] [Citation(s) in RCA: 126] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2009] [Accepted: 03/26/2009] [Indexed: 02/07/2023]
Abstract
Positron emission tomography (PET) and computed tomography (CT) complement each other's strengths in integrated PET/CT. PET is a highly sensitive modality to depict the whole-body distribution of positron-emitting biomarkers indicating tumour metabolic activity. However, conventional PET imaging is lacking detailed anatomical information to precisely localise pathologic findings. CT imaging can readily provide the required morphological data. Thus, integrated PET/CT represents an efficient tool for whole-body staging and functional assessment within one examination. Due to developments in system technology PET/CT devices are continually gaining spatial resolution and imaging speed. Whole-body imaging from the head to the upper thighs is accomplished in less than 20 min. Spatial resolution approaches 2-4mm. Most PET/CT studies in oncology are performed with (18)F-labelled fluoro-deoxy-D-glucose (FDG). FDG is a glucose analogue that is taken up and trapped within viable cells. An increased glycolytic activity is a characteristic in many types of cancers resulting in avid accumulation of FDG. These tumours excel as "hot spots" in FDG-PET/CT imaging. FDG-PET/CT proved to be of high diagnostic value in staging and restaging of different malignant diseases, such as colorectal cancer, lung cancer, breast cancer, head and neck cancer, malignant lymphomas, and many more. The standard whole-body coverage simplifies staging and speeds up decision processes to determine appropriate therapeutic strategies. Further development and implementation of new PET-tracers in clinical routine will continually increase the number of PET/CT indications. This promotes PET/CT as the imaging modality of choice for working-up of the most common tumour entities as well as some of the rare malignancies.
Collapse
Affiliation(s)
- T D Poeppel
- Department of Nuclear Medicine, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany.
| | | | | | | | | | | |
Collapse
|
99
|
Milleron B. [Lung cancer: what criteria are available to assess the post-treatment response?]. REVUE DE PNEUMOLOGIE CLINIQUE 2009; 65:123-126. [PMID: 19375054 DOI: 10.1016/j.pneumo.2008.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2008] [Accepted: 12/07/2008] [Indexed: 05/27/2023]
Affiliation(s)
- B Milleron
- UF d'oncologie pulmonaire, CancerEst, service de pneumologie, hôpital Tenon, 75020 Paris, France.
| |
Collapse
|
100
|
Kolek V, Grygarkova I, Hajduch M, Klein J, Cwiertka K, Neoral C, Langova K, Mihal V. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 152:259-66. [PMID: 19219217 DOI: 10.5507/bp.2008.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
AIM A prospective study investigated survival of patients with stage IIIA non-small-cell-lung cancer (NSCLC) treated with a combination of neoadjuvant and adjuvant chemotherapy. METHODS Consecutive chemo-naive patients with potentially operable stage IIIA NSCLC received carboplatin-based neoadjuvant treatment. Tumor cells harvested during surgery underwent methylthiazolyl tetrazolium blue (MTT) cytotoxic assay. After surgery, adjuvant chemotherapy was selected, where possible, according to MTT results. RESULTS A total of 65 patients were evaluated (31 received carboplatin/vinorelbine, 34 carboplatin/paclitaxel). The overall response rate was 67.7 % (95% confidence interval [CI]: 56.3-79.1 %) with downstaging in 52.3 % (95% CI: 40.2-64.5 %) and no significant differences between regimens. Median follow-up was 86 months: median overall survival (OS) was 32.1 months (95% CI: 7.4-46.5), median time to progression was 25.1 months (95% CI: 15.1-34.9 months) and five-year overall survival was 35.7 % (95% CI: 23.7-47.7 %). Forty-seven patients (72.3 %) underwent surgery and 43 patients received adjuvant chemotherapy. Five-year survival after tumor resection was 49.5 % (95% CI: 34.2-64.8%), median OS was 59.0 months (95% CI: 34.2-83.1) and median disease free survival after surgery was 57.3 months (95% CI: 29.5-84.4). With MTT-directed therapy, median OS was 85.1 months (95% CI: 15.4-148.6) and the 5-year survival rate was 57.0 % (95% CI: 34.5-79.5 %); the trend for longer survival failed to reach statistical significance. CONCLUSIONS A combination of carboplatin-based neoadjuvant chemotherapy, surgical resection and adjuvant chemotherapy achieved satisfactory survival rates in stage IIIA NSCLC, especially in patients with complete resection of tumor and those given MTT-directed adjuvant treatment. Our results suggest MTT testing may help optimise adjuvant chemotherapy.
Collapse
Affiliation(s)
- Vitezslav Kolek
- Departments of Respiratory Medicine, University Hospital, Olomouc, Czech Republic.
| | | | | | | | | | | | | | | |
Collapse
|